Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Increased circulating endothelial cells and microparticles in patients with psoriasis.

Martínez-Sales V, Vila V, Ricart JM, Vayá A, Todolí J, Nńñez C, Contreras T, Ballester C, Reganon E.

Clin Hemorheol Microcirc. 2015;60(3):283-90. doi: 10.3233/CH-131766.

PMID:
24002122
2.

Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value.

Reynés G, Vila V, Fleitas T, Reganon E, Font de Mora J, Jordá M, Martínez-Sales V.

PLoS One. 2013 Jul 29;8(7):e69034. doi: 10.1371/journal.pone.0069034. Print 2013.

3.

VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.

Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M, Gómez-Codina J, Montalar J, Reynés G.

Clin Transl Oncol. 2013 Nov;15(11):897-902. doi: 10.1007/s12094-013-1020-6. Epub 2013 Mar 5.

PMID:
23463593
4.

Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer.

Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M, Gómez-Codina J, Montalar J, Reynés G.

PLoS One. 2012;7(10):e47365. doi: 10.1371/journal.pone.0047365. Epub 2012 Oct 15.

5.

Circulating endothelial cells in patients with heart failure and left ventricular dysfunction.

Martínez-Sales V, Sánchez-Lázaro I, Vila V, Almenar L, Contreras T, Reganon E.

Dis Markers. 2011;31(2):75-82. doi: 10.3233/DMA-2011-0801.

6.

Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate.

Martínez-Sales V, Vila V, Ferrando M, Reganon E.

Cytotechnology. 2011 Jan;63(1):1-5. doi: 10.1007/s10616-010-9319-4. Epub 2010 Nov 4.

7.

[Circulating endothelial cells and microparticles in patients with antiphospholipid antibodies].

Martínez-Sales V, Vila V, Micó L, Contreras MT, Escandell A, Reganon E.

Med Clin (Barc). 2011 Apr 16;136(10):431-3. doi: 10.1016/j.medcli.2010.06.020. Epub 2010 Nov 3. Spanish.

PMID:
21051055
8.

Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma.

Reynés G, Vila V, Martín M, Parada A, Fleitas T, Reganon E, Martínez-Sales V.

J Neurooncol. 2011 Mar;102(1):35-41. doi: 10.1007/s11060-010-0290-x. Epub 2010 Jul 6.

PMID:
20607353
9.

What is the best biomarker for diagnosis of rejection in heart transplantation?

Martínez-Dolz L, Almenar L, Reganon E, Vila V, Sánchez-Soriano R, Martínez-Sales V, Moro J, Agüero J, Sánchez-Lázaro I, Salvador A.

Clin Transplant. 2009 Sep-Oct;23(5):672-80. doi: 10.1111/j.1399-0012.2009.01074.x. Epub 2009 Aug 27.

PMID:
19712083
10.

Erythrocyte membrane composition in patients with primary hypercholesterolemia.

Vayá A, Martínez Triguero M, Réganon E, Vila V, Martínez Sales V, Solá E, Hernández Mijares A, Ricart A.

Clin Hemorheol Microcirc. 2008;40(4):289-94. Erratum in: Clin Hemorheol Microcirc. 2009;41(2):149. Ricart, A [added].

PMID:
19126991
11.

Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.

Martínez-Dolz L, Almenar L, Reganon E, Vila V, Chamorro C, Andrés L, Martínez-Sales V, Moro J, Agüero J, Sánchez-Lázaro I, Salvador A.

J Heart Lung Transplant. 2008 Jul;27(7):760-6. doi: 10.1016/j.healun.2008.04.010. Epub 2008 Jun 6.

PMID:
18582806
12.

Inflammatory markers in stable heart failure and their relationship with functional class.

Sánchez-Lázaro IJ, Almenar L, Reganon E, Vila V, Martínez-Dolz L, Martínez-Sales V, Moro J, Agüero J, Ortiz-Martínez V, Salvador A.

Int J Cardiol. 2008 Oct 13;129(3):388-93. Epub 2007 Nov 26. Erratum in: Int J Cardiol. 2011 Feb 3;146(3):484.

PMID:
18022711
13.

Atorvastatin neutralizes the up-regulation of thrombospondin-1 induced by thrombin in human umbilical vein endothelial cells.

Martínez-Sales V, Vila V, Ferrando M, Reganon E.

Endothelium. 2007 Jul-Oct;14(4-5):233-8.

PMID:
17922340
14.

Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients.

Vila V, Martínez-Sales V, Almenar L, Lázaro IS, Villa P, Reganon E.

Int J Cardiol. 2008 Nov 12;130(2):276-7. Epub 2007 Aug 28. Erratum in: Int J Cardiol. 2011 Feb 3;146(3):484.

PMID:
17727986
15.

Erythrocyte deformability in obesity measured by ektacytometric techniques.

Solá E, Vayá A, Santaolaria ML, Hernández-Mijares A, Réganon E, Vila V, Martínez-Sales V, Corella D.

Clin Hemorheol Microcirc. 2007;37(3):219-27.

PMID:
17726251
16.

Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.

Vila V, Sales VM, Almenar L, Lázaro IS, Villa P, Reganon E.

Thromb Res. 2008;121(5):611-5. Epub 2007 Aug 10.

PMID:
17692904
17.

Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems.

Gilabert-Estellés J, Ramón LA, España F, Gilabert J, Vila V, Réganon E, Castelló R, Chirivella M, Estellés A.

Hum Reprod. 2007 Aug;22(8):2120-7. Epub 2007 Jul 3.

PMID:
17609243
18.

Diagnostic usefulness of inflammatory markers in acute cellular rejection after heart transplantation.

Sánchez-Soriano RM, Almenar L, Martínez-Dolz L, Reganon E, Martínez-Sales V, Chamorro CI, Vila V, Martín-Pastor J, Villa P, Salvador A.

Transplant Proc. 2006 Oct;38(8):2569-71.

PMID:
17098005
19.

Usefulness of von Willebrand factor in cardiac allograft vasculopathy: preliminary experience.

Chamorro CI, Almenar L, Martínez-Dolz L, Reganon E, Sánchez-Lacuesta E, Villa P, Ten F, Andrés L, Martínez-Sales V, Salvador A.

Transplant Proc. 2006 Oct;38(8):2566-8.

PMID:
17098004
20.

Sialic acid is an inflammation marker associated with a history of deep vein thrombosis.

Reganon E, Vila V, Martínez-Sales V, Vayá A, Mira Y, Ferrando F, Aznar J.

Thromb Res. 2007;119(1):73-8. Epub 2006 Feb 28.

PMID:
16500696
21.

Erythrocyte aggregation and -455G/A polymorphism of the beta-fibrinogen gene in survivors of acute myocardial infarction.

Vayá A, Breña S, Réganon E, Vila V, Martinez-Sales V, Contreras MT, Zorio E, Corella D, Aznar J.

Thromb Haemost. 2004 Jul;92(1):223-4. No abstract available.

PMID:
15213870
22.

Association between inflammation and hemostatic markers in atherothrombotic stroke.

Reganon E, Vila V, Martínez-Sales V, Vaya A, Lago A, Alonso P, Aznar J.

Thromb Res. 2003;112(4):217-21.

PMID:
14987914
23.

Influence of plasma and erythrocyte factors on red blood cell aggregation in survivors of acute myocardial infarction.

Vayá A, Falcó C, Réganon E, Vila V, Martínez-Sales V, Corella D, Contreras MT, Aznar J.

Thromb Haemost. 2004 Feb;91(2):354-9.

PMID:
14961164
24.
25.

Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.

Réganon E, Vila V, Martínez-Sales V, Vaya A, Aznar J.

Haematologica. 2002 Jul;87(7):740-5; discussion 745.

26.

Relationship between fibrinogen protein and fibrinogen function in postmyocardial infarction patients.

Réganon E, Martínez-Sales V, Vila V, Vayá A, Martinez M, Palencia MA, Aznar J.

Thromb Res. 2001 Dec 15;104(6):413-9.

PMID:
11755951
27.

Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.

Vila V, Martínez-Sales V, Réganon E, Peris E, Perez F, Ruano M, Aznar J.

Haematologica. 2001 Jul;86(7):729-34.

28.

Elevated high molecular weight fibrinogen in plasma is predictive of coronary ischemic events after acute myocardial infarction.

Reganon E, Vila V, Ferrando F, Martínez-Sales V, Fayos L, Ruano M, Aznar J.

Thromb Haemost. 1999 Nov;82(5):1403-5.

PMID:
10595627
29.

Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study.

Martínez-Sales V, Vila V, Réganon E, Goberna MA, Ferrando F, Palencia MA, Aznar J.

Haemostasis. 1998 Nov-Dec;28(6):301-6.

PMID:
10461012
30.

Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.

Réganon E, Ferrando F, Vila V, Villa P, Martínez-Sales V, Fayos L, Ruano M, Aznar J.

Haemostasis. 1998 Mar-Apr;28(2):99-105.

PMID:
10087435
31.

The effect of thrombin on the dynamic exchange between intraplatelet and extraplatelet fibrinogen.

Vila V, Martínez-Sales V, Réganon E, Aznar J.

Br J Haematol. 1997 Dec;99(3):548-54.

PMID:
9401064
32.

Fibrinopeptide A release from intraplatelet fibrinogen is related to thrombin platelet activation.

Vila V, Martinez-Sales V, Réganon E, Aznar J.

Thromb Res. 1997 May 1;86(3):263-9. No abstract available.

PMID:
9175247
33.

Unstimulated and thrombin-stimulated platelets binding to immobilized fibrinogen and fibrin on polystyrene supports.

Martínez-Sales V, Vila V, Réganon E, Aznar J.

Haemostasis. 1995 Jul-Aug;25(4):158-65.

PMID:
7557654
34.

Lack of effect of thrombin on fibrin(ogen)-endothelial cell interaction.

Réganon E, Vila V, Martínez-Sales V, Aznar J.

Cytotechnology. 1995 Jun;19(2):143-51. doi: 10.1007/BF00749769.

PMID:
22359014
35.
36.

Decreased high-molecular weight fibrinogen and impaired alpha-chain polymerization in full-term newborns.

Réganon E, Vila V, Laiz B, Gilabert J, Aznar J.

Haemostasis. 1993 May-Jun;23(3):149-58.

PMID:
8276318
37.

Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase.

Vila V, Regañón E, Aznar J, Lacueva V, Ruano M, Laiz B.

Thromb Res. 1990 Mar 1;57(5):783-94.

PMID:
2339369
38.

Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.

Regañón E, Vila V, Aznar J, Laiz B.

Clin Chim Acta. 1989 Sep 15;184(1):7-17.

PMID:
2532081
39.

Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.

Regañón E, Vila V, Aznar J, Garrido G, Estellés A, Berenguer J.

Thromb Res. 1987 Jun 1;46(5):705-14.

PMID:
3629544
40.
41.

Congenital hypofibrinogenemia and pregnancy, obstetric and hematological management.

Gilabert J, Regañon E, Vila V, Baamonde A, Villa P, Aznar J, Galbis M.

Gynecol Obstet Invest. 1987;24(4):271-6.

PMID:
3428714
42.

A rapid method for isolation of fibrinogen from human plasma by precipitation with polyethylene glycol 6,000.

Vila V, Regañón E, Llopis F, Aznar J.

Thromb Res. 1985 Sep 1;39(5):651-6. No abstract available.

PMID:
3936222
43.

[Interaction of fibrinogen with platelets. Review].

Regañón E, Aznar J, Vila V.

Sangre (Barc). 1985;30(4-A):449-57. Review. Spanish. No abstract available.

PMID:
3000005
44.

Dysfibrinogenaemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study.

Vila V, Regañon E, Fernandez-Pavon A, Aznar J.

Scand J Haematol. 1984 Nov;33(5):460-5.

PMID:
6515329
45.

Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.

Aznar J, Estellés A, Vila V, Regañón E, España F, Villa P.

Thromb Haemost. 1984 Oct 31;52(2):196-200.

PMID:
6543037
46.

Effect of calcium ions on fibrin gel formation in normal plasma.

Regañón E, Vila V, Aznar J.

Thromb Res. 1984 Aug 1;35(3):365-9. No abstract available.

PMID:
6463965
47.

Gelation of fibrinogen in plasma. A kinetic study by turbidity measurement.

Regañon E, Vila V, Aznar J.

Haemostasis. 1984;14(2):170-8.

PMID:
6735275
48.

Identification of high molecular weight derivatives of plasmic digests of cross-linked human fibrin.

Regañon E, Vila V, Aznar J.

Thromb Haemost. 1978 Oct 31;40(2):368-76. No abstract available.

PMID:
153595
49.
50.

Isolation of fibrin(ogen) degradation products from normal plasma by affinity chromatographic study.

Vila V, Regañon E, Aznar J.

Clin Chim Acta. 1978 Jul 15;87(2):245-52.

PMID:
95911

Supplemental Content

Loading ...
Support Center